2020-11-05 09:13:15 TAK Takeda
11/05/20 11/0509:13 11/05/2009:13 | Takeda Pharmaceutical to present oncology data at ASHTakeda Pharmaceutical announced that it will present 22 company-sponsored abstracts at the American Society of Hematology, or ASH, annual meeting, being held virtually December 5-8. The company's scientific research at ASH will identify approaches in advancing the treatment of hematologic cancers. Takeda will also be presenting data from its broader hematology portfolio and pipeline at the conference. A sub-analysis from the Phase 2 Pevonedistat-2001 trial will be presented in an oral session. The analysis, which focused on outcomes of the higher-risk myelodysplastic syndromes, or MDS, subgroup of the study, showed that the combination of pevonedistat and azacitidine resulted in longer event-free survival, longer duration of response and delayed transformation to acute myeloid leukemia without increasing myelosuppression, compared to treatment with azacitidine alone. Additionally, the safety profile of pevonedistat and azacitidine in combination was comparable to azacitidine alone. Despite poor outcomes, there have been no novel advances in higher-risk MDS treatment in over 10 years and new, effective therapies with favorable safety profiles that do not worsen myelosuppression are needed. Data from the interim analysis of the OPTIC trial of ICLUSIG will be presented in an oral session. The data highlighted the revised benefit-risk of ICLUSIG, a third-generation tyrosine kinase inhibitor (TKI), with the use of a response-based dosing regimen in resistant chronic-phase chronic myeloid leukemia, or CP-CML, patients, with or without mutations, who have experienced treatment failure with second-generation, or 2G, TKIs. Another oral presentation will feature a pooled sub-analysis highlighting patients from the PACE and OPTIC trials, comprising the largest patient population evaluation in a post-2G TKI setting. While CP-CML is often manageable, patients who have experienced treatment failure with prior 2G TKI therapy, especially those who are resistant to therapy, suffer from poor long-term outcomes, underscoring that there are still gaps in care for people living with CP-CML. Results from the TOURMALINE-MM2 trial will be presented in an oral session. The study was designed to evaluate the addition of NINLARO to lenalidomide and dexamethasone in newly diagnosed transplant ineligible multiple myeloma patients. While the trial did not meet the threshold for statistical significance and the primary endpoint of progression-free survival, or PFS, was not met, the study found the addition of NINLARO resulted in a 13.5 month increase in median PFS overall. In the prespecified expanded high-risk cytogenetics subgroup, the addition of NINLARO resulted in a median PFS of 23.8 months versus 18.0 months in the placebo arm. Newly diagnosed multiple myeloma patients are in need of additional proteasome inhibitor-based treatment options, as there are currently no approved options that are all-oral. Five-year follow up data from two Phase 3 frontline lymphoma studies will be featured as poster presentations. Data from the ECHELON-1 trial, which evaluated ADCETRIS in combination with doxorubicin, vinblastine and dacarbazine for previously untreated, stage III/IV Hodgkin lymphoma shows that, with extended follow-up time, the addition of ADCETRIS to AVD demonstrates a robust and sustained treatment benefit, independent of disease stage, International Prognostic Index risk factor score and PET2 status compared to ABVD, the current standard of care. Positive final analyses from ECHELON-2 which evaluated ADCETRIS in combination with CHP versus a standard care treatment in frontline treatment of patients with CD30-positive peripheral T-cell lymphoma will also be presented. The safety profile of ADCETRIS in the ECHELON-1 and ECHELON-2 trials were consistent with the established safety profile of ADCETRIS in combination with chemotherapy. |
|
---|
Earnings
|
Helix Energy reports Q1 EPS (17c), consensus 2c »
18:07
04/24/24
04/24
18:07
04/24/2418:07
HLX
Helix Energy
Reports Q1 revenue… Available to The Fly Members Only Breaking content available to members only. Sign up or login for access. Create FREE Account |
Upgrade
|
AkzoNobel just upgraded at Goldman Sachs, here's why »
18:07
04/24/24
04/24
18:07
04/24/2418:07
AKZOY
AkzoNobel
Goldman Sachs upgraded… Available to The Fly Members Only Breaking content available to members only. Sign up or login for access. Create FREE Account |
Hot Stocks
|
IBM says its strategic partnerships have 'great velocity' »
18:05
04/24/24
04/24
18:05
04/24/2418:05
IBM
IBM
Says demand profile… Available to The Fly Members Only Breaking content available to members only. Sign up or login for access. Create FREE Account |
Hot Stocks
|
Mativ names Kimberly Ritrievi chair of the board »
17:48
04/24/24
04/24
17:48
04/24/2417:48
MATV
Mativ
Mativ Holdings announced… Available to The Fly Members Only Breaking content available to members only. Sign up or login for access. Create FREE Account |
Earnings
|
First Bancshares reports Q1 adjusted EPS 65c, consensus 59c »
17:48
04/24/24
04/24
17:48
04/24/2417:48
FBMS
First Bancshares
M. Ray "Hoppy"… Available to The Fly Members Only Breaking content available to members only. Sign up or login for access. Create FREE Account |
Hot Stocks
|
Ford CFO says transforming company into 'more resilient business' »
17:38
04/24/24
04/24
17:38
04/24/2417:38
F
Ford
CFO John Lawler stated on… Available to The Fly Members Only Breaking content available to members only. Sign up or login for access. Create FREE Account |
Hot Stocks
|
Ford CEO says FY24 CAPEX will likely be at low end of guided range »
17:35
04/24/24
04/24
17:35
04/24/2417:35
F
Ford
CEO Jim Farley says:… Available to The Fly Members Only Breaking content available to members only. Sign up or login for access. Create FREE Account |
Hot Stocks
|
IBM sees Q2 constant currency revenue growth 'consistent' with FY goal
17:33
04/24/24
04/24
17:33
04/24/2417:33
IBM
IBM
|
Hot Stocks
|
IBM says Q1 free cash flow 'strongest in years' »
17:32
04/24/24
04/24
17:32
04/24/2417:32
IBM
IBM
HashiCorp
Says Q1 free cash flow of… Available to The Fly Members Only Breaking content available to members only. Sign up or login for access. Create FREE Account |
Hot Stocks
|
Ford CEO says Q1 'had a lot of great green shoots' »
17:32
04/24/24
04/24
17:32
04/24/2417:32
F
Ford
CEO Jim Farley stated:… Available to The Fly Members Only Breaking content available to members only. Sign up or login for access. Create FREE Account |
Earnings
|
Avid Bioservices still sees FY24 revenue $137M-$147M, consensus $138.66M
17:32
04/24/24
04/24
17:32
04/24/2417:32
CDMO
Avid Bioservices
|
Earnings
|
Avid Bioservices reports Q3 EPS (9c), consensus (5c) »
17:31
04/24/24
04/24
17:31
04/24/2417:31
CDMO
Avid Bioservices
Reports Q3 revenue… Available to The Fly Members Only Breaking content available to members only. Sign up or login for access. Create FREE Account |
Recommendations
|
Interpublic Group price target raised by $1 at Macquarie, here's why »
17:29
04/24/24
04/24
17:29
04/24/2417:29
IPG
Interpublic Group
Macquarie raised the… Available to The Fly Members Only Breaking content available to members only. Sign up or login for access. Create FREE Account |
Earnings
|
Amerant Bancorp reports Q1 EPS 31c, consensus 36c »
17:29
04/24/24
04/24
17:29
04/24/2417:29
AMTB
Amerant Bancorp
Net interest margin was… Available to The Fly Members Only Breaking content available to members only. Sign up or login for access. Create FREE Account |
Earnings
|
WM lowers 2024 revenue growth view to 5%-5.75% from 6%-7%, consensus $21.74B »
17:27
04/24/24
04/24
17:27
04/24/2417:27
WM
WM
Raises 2024 adjusted… Available to The Fly Members Only Breaking content available to members only. Sign up or login for access. Create FREE Account |
Earnings
|
WM reports Q1 EPS $1.75, consensus $1.50 »
17:25
04/24/24
04/24
17:25
04/24/2417:25
WM
WM
Reports Q1 revenue… Available to The Fly Members Only Breaking content available to members only. Sign up or login for access. Create FREE Account |
Periodicals
|
BHP mulls possible takeover of Anglo American, Bloomberg reports »
17:24
04/24/24
04/24
17:24
04/24/2417:24
BHP
BHP Group
Anglo American
BHP Group (BHP) is… Available to The Fly Members Only Breaking content available to members only. Sign up or login for access. Create FREE Account |
Earnings
|
Teradyne sees Q2 EPS 64c-84c, consensus 60c »
17:24
04/24/24
04/24
17:24
04/24/2417:24
TER
Teradyne
Sees Q2 revenue… Available to The Fly Members Only Breaking content available to members only. Sign up or login for access. Create FREE Account |
Earnings
|
Teradyne reports Q1 EPS 51c, consensus 33c »
17:23
04/24/24
04/24
17:23
04/24/2417:23
TER
Teradyne
Reports Q1 revenue $600M,… Available to The Fly Members Only Breaking content available to members only. Sign up or login for access. Create FREE Account |
Syndicate
|
Dyadic International files to sell 3.35M shares of common stock for holders
17:22
04/24/24
04/24
17:22
04/24/2417:22
DYAI
Dyadic International
|
Earnings
|
Sleep Number sees Q2 revenue down high-single digits, consensus $428M »
17:21
04/24/24
04/24
17:21
04/24/2417:21
SNBR
Sleep Number
Sees Q2 adjusted EBITDA… Available to The Fly Members Only Breaking content available to members only. Sign up or login for access. Create FREE Account |
Earnings
|
Core Laboratories sees Q2 EPS 19c-23c, consensus 21c »
17:19
04/24/24
04/24
17:19
04/24/2417:19
CLB
Core Laboratories
Sees Q2 revenue… Available to The Fly Members Only Breaking content available to members only. Sign up or login for access. Create FREE Account |
Earnings
|
Celestica raises FY24 EPS view to $3.30 from '$2.70 or more', consensus $2.93 »
17:18
04/24/24
04/24
17:18
04/24/2417:18
CLS
Celestica
Raises FY24 revenue view… Available to The Fly Members Only Breaking content available to members only. Sign up or login for access. Create FREE Account |
Earnings
|
Core Laboratories reports Q1 non-GAAP EPS 19c, consensus 16c »
17:18
04/24/24
04/24
17:18
04/24/2417:18
CLB
Core Laboratories
Reports Q1 revenue… Available to The Fly Members Only Breaking content available to members only. Sign up or login for access. Create FREE Account |
Earnings
|
Celestica sees Q2 EPS 75c-85c, consensus 71c »
17:17
04/24/24
04/24
17:17
04/24/2417:17
CLS
Celestica
Sees Q2 revenue… Available to The Fly Members Only Breaking content available to members only. Sign up or login for access. Create FREE Account |